A B S T R A C T Eight normal subjects were administered tracer amounts of a 14C-labeled thyroxine, L-[tyrosyl-14C] T4, by multiple injections. Then serial blood samples were collected for isolation of the thyroxine, triiodothyronine, and tetraiodothyroacetic acid fractions by a combination of column and paper chromatographies. The chromatographic artifacts were corrected by adding to the sera a purified 3H-labeled thyroxine, D,L-[a,,f-3H] T4 immediately after the separation of sera from blood. 1-2% of the serum 14C radioactivity was observed in the triiodothyronine fraction and 2-4% of the serum 14C radioactivity was observed in the tetraiodothyroacetic acid fraction. Complete kinetic studies of thyroxine and triiodothyronine were compared in the same individual in four of the subjects. The extrathyroidal conversion rates of thyroxine to triiodothyronine were calculated from data obtained during both the injection and the postinjection periods as functions of the 14C-labeled thyroxine and triiodothyronine remaining in the body at time t and their fractional turnover rates. The average daily rate of the extrathyroidal conversion of thyroxine to triiodothyronine was 4% of the extrathyroidal thyroxine pool or 33% of the total thyroxine production. The amount of triiodothyronine generated by this pathway (22 ,ug/day) was found to contribute 31% of the extrathyroidal triiodothyronine pool or 41% of the daily triiodothyronine production. This pathway is a major source of triiodothyronine production. The extrathyroidal conversions of thyroxine to triiodothyronine and tetraiodothyroacetic acid are major metabolic pathways of thyroxine in normal man.
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INTRODUCTION
Since the presence of triiodothyronine (T3)1 in human plasma was first reported in 1952, the source of this circulating hormone has never been clearly defined (1) .
It is known that some triiodothyronine is released by the thyroid gland into the blood. At least in the lower animals, the concentration of triiodothyronine is higher in the venous effluent than the arterial blood of the thyroid (2, 3) . The possibility of extrathyroidal de- iodination of thyroxine (T4) to triiodothyronine had also been entertained by many investigators. However, in the early human studies, the attempts to identify I3'l-labeled T3 following a single injection of 1311-labeled T4 only yielded equivocal results (4, 5) . Volpert, Greenberg, and Werner found triiodothyronine in both normal pituitary and transplanted pituitary tumor of mice after the injection of 1311-labeled thyroxine (6) . Albright, Larson, and Tust detected triiodothyronine after incubating I3'l-labeled thyroxine with rat kidney tissue (7) . While there were such exceptions, most animal studies by either in vivo or in vitro techniques also failed to substantiate deiodination of T4 as a significant pathway that gives rise to circulating T3 (6) (7) (8) . More recently Braverman, Ingbar, and Sterling analyzed the total serum T4 and T3 in hypothyroid patients maintained on pharmacological doses of L-thyroxine (9) . The T3 :T4 ratios in their sera were found to be higher than the ratio in the ingested L-thyroxine preparation. These same investigators also administered multiple injections of 125I-labeled thyroxine to two athyreotic patients. Approximately 1-2% of the serum radioactivity was found to be in the triiodothyronine fraction and twice that in the tetraiodothyroacetic acid (Tetrac) fraction. This study strongly suggested the presence of extrathyroidal conversion of T4 to T3 in man. In a study by Pittman, Nakafuji, and Read in normal men, 14C-labeled T3 and Tetrac were also regularly observed after repeated intravenous injections of '4C-labeled T4 (10) . The present report contains our measurement of the rate of this extrathyroidal conversion of T4 to T3 in similarly prepared normal subjests. T4 and T3 kinetic studies were compared in the same individuals in order to define the biological significance of the pathway of extrathyroidal conversion of T4 to T3 in man.
METHODS
Materials. Two types of radiothyroxines were used in the studies. One radiothyroxine was labeled with 14C in the nonphenolic ring and the alanine side chain, L-[tyrosyl-14C] T4. It was synthesized by the method of Shiba and Cahnmann by Amersham-Searle Corp., Arlington Heights, Ill. and it had a specific activity of 135 mCi/mmole (11) . The L-[tyrosyl-54C] T4 was used to calculate the T4 to T3 conversion rates. The other radiothyroxine was labeled with 3H in the alpha and beta carbons of the side chain, D,L-[a,13-3H] T4, with a specific activity of 125 mCi/mmole. The D,L-[a,,6-5H] T4 was synthesized by Dr. J. Nunez with the method of Nunez, Jacquemin, and Roche (12) . The sample contained primarily L-thyroxine but it was not free of some D-thyroxine. The D,L-[a,8-3H] T4 was used only as a methodological control in the correction for artifactual T4 deiodination and for the calculation of T4 recoveries during our chromatographic manipulations. In addition, a 13I-labeled triiodothyronine, L-[3'-1311] T3 was purchased from the Abbott Laboratories, North Chicago, Ill., specific activity 1.79 X 104 mCi/mmole. The purity of radioactive T4 and T3 was 98% or greater before use. They were prepared for injection in a sterile solution of 1% ethanol, 0.9% scdium chloride, and 1% human albumin as described previously (13) . Every thyroxine dose was chromatographed in at least two solvent systems and the presence of triiodothyronine was assayed directly in a liquid scintillation counter as de- Subjects. Studies were carried out in eight young, healthy male subjects free of any past history or family history of thyroid disorder. The details of their clinical information are listed in T4 standard was 7.9-19.0%. The 14C and 3H activities were assayed in a dioxane scintillator (1% PPO, 0.05% POPOP, and 5% naphthalene) with a liquid scintillation counter (Nuclear-Chicago Corporation, Des Plaines, Ill.). The gamma radioactivity of 1311 was assayed in a well scintillation counter (Nuclear-Chicago Corporation, Des Plaines, Ill.).
The half-times of T4 were obtained from the 14C data 24 hr after the last injection of L-[tyrosyl-14C] T4. The disappearance of 14C radioactivity in blood was followed for 9-12 days during which time five to seven samples were collected from each subject for the calculation of half-times.
In the study of T3 kinetics, the 1311 activities in both the native serum and the protein precipitate were assayed. The latter was used in our calculation. The serum was precipitated by the following procedure. To 1.0 ml of serum was first added 25 ,ug/ml of carrier sodium iodide and enough propylthiouracil to make a 10-5 M solution, followed by 1.0 ml of cold 20% trichloroacetic acid. The resulting precipitate was washed three times with cold 5% trichloroacetic acid.
The measurements of the total serum T4 and T3 were carried out by the Boston Medical Laboratory, Waltham, Mass. The serum T4 was measured by a modification of the method of Murphy and Pattee (15) . The serum T3 was measured according to a modified method of Sterling, Bellabarba, Newman, and Brenner (14) .
Calculation. The serum radioactivity was plotted as a function of time. The half-time (tj) of T4 or T3 was obtained from the respective linear regression. The fractional turnoverrate (K) and the zero time volume of distribution (Vd) were calculated by a method similar to that described by Ingbar and Freinkel (16) . The total body pool was derived from the product of the serum concentration and the volume of distribution. The daily production rate (or disposal rate) was calculated from the product of the serum concentration, the volume of distribution, and the fractional turnover-rate of T4 or T3. In the study of T3 kinetics, the problem of iodoproteins that arises as a product of T3 degradation was avoided by using only the data collected between 24-72 hr after an injection of L-[3'-1311] T3 (17 
For A = 0, i.e. for t > t*, the solution to (1) is
[T4] = Ce-K4t (3) where C must be evaluated from the initial conditions. In this case, the initial conditions are that at t = t* [T4] is given by, from (2), A (1 -e-K4t*)/K4. Using this, equation (3) becomes
The extrathyroidal conversion of T4 to T3 can be described by
As was the case for [T4], the solution of (5) -K4(1 -e-K3t*)e-K3(t-t*) (7) For t < t*, the extrathyroidal conversion rate, X, can be found, after dividing (6) by (2), as
For t > t*, X can be found by dividing (7) by (4) .
K3A-K4( e: ,-1 e(KX-K4)t [T4]
RESULTS
The clinical information of our subjects are summarized in Table I In all serum samples studied, 14C radioactivity was consistently found in the T4, T3, and Tetrac fractions. The 14C-labeled Tetrac was always found in equal or slightly larger amounts than the 14C-labeled T3. The 14C radioactivity in the T3 fraction represented 1.56 4±0.50% of the total 14C radioactivity in serum. The recovery of Tetrac was not measured. Of the total radioactivity applied to the chromatogram paper, 0.4-4.3% was found in the Tetrac fraction.
In all the subjects studied trace amounts of D,L-[a43-3H] T4 were added to sera either in vitro or in vivo as a control. The need of such a control is shown in Fig. 2 samples were collected. The two-dimensional paper chromatograms of the deproteinized sera were developed in a solvent system of hexane:tertiary amyl alcohol:2 N ammonium hydroxide in both directions. The T4, and T3 areas were cut out and assayed for 14C and 3H radioactivities.
stant. Therefore, the radioactivity found in the T3 fraction was contributed primarily by the in vivo conversion of radioactive T4 to T3 in addition to the artifacts mentioned before. It is assumed that during chromatographic manipulations the 3H and 14C-labeled thyroxines contributed similar fractions of their respective radioactivities to the T3 area on paper chromatograms due to T4 remaining in the T3 fraction and due to T4 to T3 conversion in vitro. Therefore, the fraction of 3H activity was used to correct for the contribution of 14C due to these artifacts in the T3 area. When this value was equal to or less than the labeled T3 contaminant in the original T4 injection dose, no net correction was made. In actuality, no net correction was necessary in most of our calculations of [T3]. For example: to 10 ml serum of J. Mu. trace amounts of l31-labeled T3 standard were added. To another 10 ml serum of J. Mu. trace amounts of a 3H-labeled T4 standard were added. After all the chromatographic manipulations, 62 dpm of 3H was recovered from the T3 area of the final paper chromatogram or 0.48% of the total 3H activity applied to the paper. From the same T3 area, 55 dpm of 14C activity was recovered. The over-all T3 recovery calculated from the 131J T3 standard was 17.7%. Since the per cent of 3H-labeled T3 contaminant in the original injection dose of 3H-T4 was approximately the same (0.50%) as that recovered in the T3 area, no correction for artifacts was made. Therefore, the serum concentration of 14C-labeled T3 = 5.5 dpm + 17.7 X 100 = 31 dpm ml-'. The chromatographic data are summarized in Table II The Ta radioactivity in serum (dpm ml-') = Ts radioactivity on paper chromatogram (dpm) --total serum volume used (ml) * . per cent of Ta recovery X 100. Ts radioactivity in the body (dpm) = Ts radioactivity in serum (dpm ml-') X Ta volume of distribution (1) X 1,000.
agree with those calculated from equations (2) and (4) (2) and (8) or equations (4) and (9) gave essentially similar results. They were grouped together in Table V . The mean conversion rate from the entire group of six subjects was 4.16 4 1.44% of extrathyroidal T4 pool per day (mean -+SD), or 33. 4 11.0% of T4 production per day. In four of the six subjects the amount of T3 generated by the pathway of extrathyroidal conversion was calculated with each subject's own kinetics of T4 and T3. For the remaining two subjects, the amount of T3 converted from T4 was calculated with the mean values obtained from the other four subjects. The results showed that 26.1 ±9.5 jsg of thyroxine was metabolized each day by the pathway of extrathyroidal conversion which gave rise to an average of 21.9 ±47.9
Ag of T3. The amount of T3 thus derived constituted an average of 31.0 ± 14.7% of the total extrathyroidal pool of T3. More important, it constituted an average of 41.2 ±20.9% of the daily production rate of T3.
DISCUSSION
In the past, in vivo evidence of extrathyroidal conversion of T4 to T3 were sought by many studies in animals and in man. Most of these studies employed the technique of administering radiothyroxine in one injection, and then the presence or absence of radioactive T3 was demonstrated by chromatography. The conclusions of most of these studies were equivocal and controversial (6) . This controversy can be explained partly by the kinetics of T3 itself. As shown by the results of our present study and that reported by other investigators, this hormone has a fractional turnover-rate of 70% per day and a half-time of approximately 1 day (17) (18) (19) (20) . After multiple injections of L-[tyrosyl-'4C] T4, the 14C labeled T3 constituted only 1.6% of the total serum radioactivity. Therefore, demonstration of the extrathyroidal conversion of T4 to T3 amidst the multiple artifacts inherent of chromatographic techniques is fraught with pitfalls. (a) Thyroidal contribution of T3, (b) contamination of the T4 dose by T3, (c) incomplete separation of the T4 and T3 fractions, and (d) artifactual production of T3 during chromatography are some of the pitfalls.
The procedures followed in our present study were adopted to overcome these very pitfalls. The radiothyroxines used in the study were labeled with 14C or 3H rather than with a radioiodine, therefore the thyroidal contribution of T3 in blood was excluded from our calculation. The L-[tyrosyl-14C] T4 doses were chromato- graphed at the beginning and the end of injection period an injection of D,L-[Eja-3H] T4, the 3H activity in the to determine the exact amounts of contamination by T3 fraction of blood rose with time suggesting that thc 14C-labeled T3 which was a very small correction in the formation of 3H-T3 was primarily due to metabolie present study since most of the sera were collected events. If the 3H radioactivity in the T3 fraction was 5 days after the last 14C-T4 injection. As shown in solely due to contamination of the T4 dose by T3, the Fig. 3 , when serial blood samples were collected after 3H activity should have cleared at the same rate as X, the extrathyroidal conversion rate. The results of the first four subjects were calculated from their own kinetic data (Table IV) . The results of the last two subjects were calculated from the mean values of the first four subjects listed in Table IV (9) . All our serum samples were analyzed by two-dimensional chromatography at the final stage of study. A solvent of hexane: tertiary amyl alcohol: ammonia was used in developing the chromatograms in both directions because this solvent system is particularly suitable in the separation of T4, T3, Tetrac, and triiodothyroacetic acid (21) . The metabolism of T4 to Tetrac was observed in animals by many observers before (22) (23) (24) and was also observed by Braverman et al. in man (9) . Our results agreed with the last report and showed that in a state of near isotopic equilibrium, "4C-labeled Tetrac was found in equal or slightly larger amounts than 4C-labeled T3. Since the clearance rate of Tetrac was reported to be slower than that of T3 by some early studies, the higher serum concentrations of "4C-labeled Tetrac could not be interpreted to mean a higher production rate for Tetrac than for T3 in man (25) . Recently, Pittman, Read, Chambers, and Nakafuji (13) ratios of the urine were the same as the 3H/'4C ratios of the T4 dose suggesting that the deiodinated metabolites of T4 retained an intact diphenyl ether structure. Therefore, most likely the T3 and Tetrac formed from T4 metabolism are in turn deiodinated before urinary excretion without undergoing cleavage of the diphenyl ether.
Detailed study of the T4 and T3 kinetics were carried out in the same individual in four of our subjects. Our study of T4 showed a mean t' of 5.62 days, mean turnover-rate of 12 (26, 16, 27 (18) . There are several reported methods for the measurement of stable T3 in serum employing column and paper chromatographies as well as gas-liquid chromatography (14, 28, 29) . The value of T3 in normal serum by these three methods is well above 200 ng per 100 ml. However, there appeared to be no agreement on the value of stable T3 in normal serum (30) . Apparently no satisfactory correction for chromatographic artifacts as discussed earlier in this paper has been found. The stable serum T3 in our study was measured by a modified method of Sterling et al. (14) in the Boston Medical Laboratory, Waltham, Mass. Measured by this method the T3 concentration in normal serum is 150-250 ng per 100 ml which must be taken as an approximation. However, for clinical purposes and in normal subjects this method has been found very reproducible. In the presence of elevated serum T4, the measurement of T3 becomes too high partly due to incomplete separation of the T4 and T3 fractions. Braverman et al. (9) reported that their athyreotic patients, whose serum T4 measurements were elevated to 2-3 times the normal value, were eumetabolic despite serum T3 measurements in the range of 269-680 ng per 100 ml (9) . This dis-crepancy can be explained partly by the fact that in the presence of excessive T4, the T4 contamination of the T3 fraction becomes significant in displacement analysis and falsely elevates the T3 measurements.
The sera studied were collected from our subjects both during and after the injection period of L-[tyrosyl-14C] T4. While these different conditions required different methods of calculation, they yielded similar results. Our calculation yielded a mean extrathyroidal conversion rate of T4 to T3, 4.16% of the extrathyroidal T4 per day. More significantly this pathway was shown to metabolize approximately 33% of the T4 produced daily. Therefore, approximately 22 1Ag of T3 was generated from the extrathyroidal conversion of T4. However the contribution of this 22 Mg of T3 to the over-all production of T3 is more difficult to assess because of our reservation over the stable T3 determinations. If these determinations were valid, then extrathyroidal conversion of T4 to T3 contributed 41% of the total daily production of T3.
In conclusion, our study conclusively shows that the pathways of extrathyroidal conversion of T4 to T3 and T4 to Tetrac are operative in normal men. The amount of T4 metabolized by this pathway accounts for 33% of the total T4 production and contributes 41% of the total T3 production each day. Therefore, the extrathyroidal conversion of T4 to T3 is a physiologically important pathway in normal man.
